Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma"

Affiliations

¹ Vanderbilt-Ingram Cancer Center, Nashville, Tennessee. Electronic address: olalekan.oluwole@vumc.org.
² Precision HEOR, Oakland, California.
³ Kite Pharma, a Gilead Company, Santa Monica, California.
⁴ Precision HEOR, Vancouver, British Columbia, Canada.
⁵ Moffitt Cancer Center, Tampa, Florida.

Free article

Comment

Olalekan O Oluwole et al. Biol Blood Marrow Transplant. 2020 Dec.

Free article

. 2020 Dec;26(12):e335-e336.

doi: 10.1016/j.bbmt.2020.09.009. Epub 2020 Sep 18.

¹ Vanderbilt-Ingram Cancer Center, Nashville, Tennessee. Electronic address: olalekan.oluwole@vumc.org.
² Precision HEOR, Oakland, California.
³ Kite Pharma, a Gilead Company, Santa Monica, California.
⁴ Precision HEOR, Vancouver, British Columbia, Canada.
⁵ Moffitt Cancer Center, Tampa, Florida.

No abstract available

Comment on

Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma.
Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL. Oluwole OO, et al. Biol Blood Marrow Transplant. 2020 Sep;26(9):1581-1588. doi: 10.1016/j.bbmt.2020.06.008. Epub 2020 Jun 17. Biol Blood Marrow Transplant. 2020. PMID: 32561336
Letter to the Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma".
Zhang J, Li J, Ma Q, Yang H, Signorovitch J, Wu E. Zhang J, et al. Biol Blood Marrow Transplant. 2020 Dec;26(12):e333-e334. doi: 10.1016/j.bbmt.2020.08.032. Epub 2020 Sep 18. Biol Blood Marrow Transplant. 2020. PMID: 32950695 No abstract available.